...
首页> 外文期刊>Journal of the American Society of Nephrology: JASN >Late prednisone withdrawal in cyclosporine-treated kidney transplant patients: a randomized study.
【24h】

Late prednisone withdrawal in cyclosporine-treated kidney transplant patients: a randomized study.

机译:环孢素治疗的肾移植患者中强的松的晚期撤药:一项随机研究。

获取原文
获取原文并翻译 | 示例

摘要

Prednisone in combination with cyclosporine and/or azathioprine is commonly used after kidney transplantation to prevent graft rejection. Long-term use of prednisone can give rise to multiple side effects and morbidity. This randomized study was conducted to find out if prednisone could be withdrawn in recipients at least 1 yr after kidney transplantation. Eighty-four such recipients of a cadaveric kidney with stable renal function on cyclosporine and prednisone were randomized to continue prednisone (N = 42) or to withdraw prednisone in a 2-month period (N = 42). The main end point was the percentage of successful prednisone withdrawal. Both groups were compared for the incidence of infections and cardiovascular risk factors and for the incidence and cause of deterioration of renal function. All patients had a 14-month follow-up. In 67% (N = 28) of the patients, prednisone could be withdrawn successfully. Acute rejection was the main cause of withdrawal failure (N = 11, 26%). No grafts were lost due to rejection. In the prednisone withdrawal group, a tendency was noted for a lower incidence of infections (difference: 17%; 95% confidence interval [CI]: -4% to 37%). After withdrawal, less antihypertensive drugs were necessary to control hypertension (difference: 0.5 drugs/patient; 95% CI: -0.9 to -0.1) and 35% less patients (23 of 41 versus nine of 42) needed cholesterol-lowering drugs (95% CI: -54% to -15%). A reduction of the frequency of patients with Type II diabetes mellitus was found (difference 10%; 95% CI: -24% to 5%) with a decrease of glycosylated hemoglobin (difference: 0.4 mmol/L; 95% CI: 0.1 to 0.8). Disappearance of moonface was found in 25% of the patients. Elective withdrawal of prednisone > 1 yr after postmortal kidney transplantation can be accomplished safely provided that patients are controlled frequently. Beneficial effects were found regarding hypertension, hypercholesterolemia, hyperglycemia, and appearance.
机译:肾移植后通常使用泼尼松与环孢霉素和/或硫唑嘌呤的组合以防止移植排斥。长期使用泼尼松可能引起多种副作用和发病率。进行了这项随机研究,以了解肾移植后至少1年是否可以在接受者中撤出泼尼松。八十四名在环孢素和泼尼松上具有稳定肾功能的尸体肾脏接受者被随机分配为继续泼尼松(N = 42)或在两个月内撤出泼尼松(N = 42)。主要终点是泼尼松成功戒断的百分比。比较两组的感染发生率和心血管危险因素,以及肾功能恶化的发生率和原因。所有患者均进行了14个月的随访。在67%(N = 28)的患者中,泼尼松可以成功撤出。急性排斥反应是戒断失败的主要原因(N = 11,26%)。没有移植物因排斥反应而丢失。在泼尼松戒断组中,感染的发生率呈下降趋势(差异:17%; 95%置信区间[CI]:-4%至37%)。停药后,控制高血压所需的降压药减少(差异:0.5种药物/患者; 95%CI:-0.9至-0.1),需要降低胆固醇的药物的患者减少了35%(41种中的23种比42种中的9种) %CI:-54%至-15%)。发现II型糖尿病患者的频率降低(差异10%; 95%CI:-24%至5%),而糖基化血红蛋白降低(差异:0.4 mmol / L; 95%CI:0.1至2.5%)。 0.8)。在25%的患者中发现了月球面消失。只要经常控制患者,在死后肾脏移植后选择强的松> 1年的选择撤药可以安全地完成。发现对高血压,高胆固醇血症,高血糖症和外观有有益作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号